Skip to main content

Developing a collection of clinical, imaging and biologic specimens to identify biological markers of Parkinson’s risk, onset and progression

Research Question:
Does collecting data from participants with Parkinson's Disease allow identification of markers of disease?

Basic Study Information

The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of the study is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.

Location: University of Rochester
Study Reference #: STUDY00005089

Lead Researcher (Principal Investigator)

Lead Researcher:  Ruth Schneider

Study Contact Information

Study Coordinator: Anisha Singh
Phone: (585) 341-7515

Additional Study Details

Study Details:
Individuals ages 30 years and older who do not have a diagnosis of Parkinson's Disease are currently eligible to participate. We are currently recruiting only healthy controls and prodromal participants.

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search